VANCOUVER, British Columbia, Dec. 30, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) a developer of marijuana and alcohol breath testing devices, is pleased to announce that it has received its first product orders for BreathLogix devices and related accessories from its exclusive distribution partner in Australia, Breathalyser Sales & Service Pty Ltd. (“Breathalyser SSP”). This order represents Cannabix’s first international distributor order for its BreathLogix alcohol screening product line.
Earlier this year, Cannabix entered into an exclusive distribution agreement with Breathalyser SSP for Australia, New Zealand, and the Pacific Islands to represent the Company’s BreathLogix autonomous (unmanned) alcohol breathalyzer devices (see Figures 1 and 2).
BreathLogix devices provide rapid breath alcohol checks, capture a photo of the user simultaneously, and deliver real-time alerts to managers—helping prevent workplace injuries and property damage caused by alcohol impairment.
Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use for the Australian market. The company operates regional offices in Perth, Melbourne, and Brisbane and serves clients across sectors including mining, oil and gas, industrial, trucking, warehousing, and technology.
Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is excited to receive first orders from Australia for its BreathLogix Alcohol devices as the Company works to deliver innovative new technologies to market. Breathalyser Sales & Service Pty Ltd has many years of experience with various industries deploying breath alcohol testing systems to improve worker safety.”
Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, “BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia’s oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, unmanned employee alcohol screening is a major segment of our business.”
Figure 1. BreathLogix Alcohol Screening Devices
Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
BreathLogix Alcohol Screening Devices
BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.
BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.
The Company reports that it will not proceed with the previously announced non-brokered LIFE private placement. Recent orders for the BreathLogix product line, coupled with increased ramp-up activity from distribution partners for the Marijuana Breath Test solution, indicate that the Company’s near-term capital requirements will be reassessed in early 2026.
The Company has entered into an arm’s length 30-day investor awareness campaign with ShareholdersIPR LLC. ShareholdersIPR, will provide a research report, help disseminate the report through social media and online web forums (“Services”). As consideration for the Services, the company will pay USD $2,450. The Company will not issue any securities to ShareholdersIPR as compensation for its Services. The principal of ShareholdersIPR LLC is Thomas K. Shea ([email protected], 404-314-5580, Marietta, Georgia).
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company’s products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/bbe8a96d-67b5-4446-902b-98bcd9705293
https://www.globenewswire.com/NewsRoom/AttachmentNg/aa691629-ff88-4889-b0bf-665f8d3f1b60
